|
|
| (117 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32257173|t=ä. An evidence-based framework for priority clinical research questions for COVID-19 |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32133578|t=2020. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32315723|t=ä. The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event |pdf=|usr=}}
| + | |
| − | {{tp|p=32109444|t=2020. Coronavirus 2019-nCoV: A brief perspective from the front line |pdf=|usr=}} ''w structure of virus''
| + | |
| | | | |
| | | | |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| − | {{tp|p=32353109|t=ä. COVID-19 Pandemic: Considerations for Safe Medication Use in Older Adults with Multimorbidity and Polypharmacy |pdf=|usr=}}
| |
| − | {{tp|p=32343984|t=ä. COVID-19: before stopping specific infection control measures, be sure to exclude the diagnosis |pdf=|usr=}}
| |
| − | {{tp|p=32201156|t=ä. Multiple parameters required for diagnosis of COVID-19 in clinical practice |pdf=|usr=}}
| |
| | | | |
| − | ----
| + | *'''[[Respiration mgmt]]''' |
| | | | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | | | |
| − | *'''[[Structure of covid19]]'''
| |
| − | {{tp|p=32361692|t=2020. How the COVID-19 Overcomes the Battle? An Approach to Virus Structure |pdf=|usr=}}
| |
| − | {{tp|p=32306836|t=2020. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment |pdf=|usr=}}
| |
| − | {{tp|p=32145215|t=ä. Identification of the hyper-variable genomic hotspot for the novel coronavirus SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | | | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| − | *'''[[Target binding and uptake]]'''
| |
| − | {{tp|p=32344526|t=2020. COVID-19 and RAS: Unravelling an Unclear Relationship |pdf=|usr=}}
| |
| − | {{tp|p=32274964|t=2020. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin |pdf=|usr=}}
| |
| − | {{ttp|p=32169481|t=2020. COVID-19 spike-host cell receptor GRP78 binding site prediction |pdf=|usr=}}
| |
| − | {{tp|p=32092392|t=2020. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Structure of covid19]]''' |
| | + | |
| | + | |
| | + | *'''[[Target binding and uptake]]''' |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32277967|t=ä. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32325129|t=ä. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32315725|t=ä. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32283159|t=ä. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32283164|t=ä. Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China |pdf=|usr=}}
| |
| − | {{tp|p=32283162|t=ä. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32358956|t=ä. Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19 |pdf=|usr=}}
| |
| | | | |
| − | {{tp|p=32227123|t=ä. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia |pdf=|usr=}}
| + | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| | | | |
| | | | |
| − | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]'''
| |
| | | | |
| | + | *'''[[Pathobiology]]''' |
| | + | |
| | + | |
| | + | *'''[[Disease Models]]''' |
| | + | |
| | + | |
| | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| Zeile 64: |
Zeile 56: |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32311448|t=ä. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Hematology]]'''
| |
| | | | |
| − | *'''[[Microvascular]]'''
| |
| | | | |
| − | *'''[[Heart]]'''
| |
| − | {{tp|p=32209382|t=ä. The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Hematology]]''' |
| | | | |
| − | *'''[[Neurology, ophthalmology, orl]]'''
| |
| − | *'''[[Dermatology]]'''
| |
| | | | |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| − | {{tp|p=32363540|t=ä. Bowel Necrosis in the Setting of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32298767|t=ä. COVID-19: Abnormal liver function tests |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Heart]]''' |
| | | | |
| − | *'''[[Kidney, urology]]'''
| |
| | | | |
| − | ----
| |
| | | | |
| | + | *'''[[Neurology, ophthalmology, orl]]''' |
| | | | |
| − | *'''[[Pathobiology]]'''
| |
| − | {{tp|p=32283163|t=ä. A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32348495|t=ä. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with disease severity in COVID-19 |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Disease Models]]'''
| |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]''' | + | *'''[[Dermatology]]''' |
| − | ----
| + | |
| | | | |
| | | | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| − | {{tp|p=32209385|t=ä. Profile of specific antibodies to SARS-CoV-2: The first report |pdf=|usr=}}
| |
| − | {{tp|p=32360885|t=ä. Value and Challenges: Nucleic Acid Amplification Tests for SARS?CoV-2 in Hospitalized COVID-19 Patients |pdf=|usr=}}
| |
| − | {{tp|p=32335175|t=ä. Reliability and usefulness of a rapid IgM?IgG antibody test for the diagnosis of SARS-CoV-2 infection: a preliminary report |pdf=|usr=}}
| |
| − | {{tp|p=32335168|t=ä. Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32298676|t=ä. Saliva is a reliable tool to detect SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]''' | + | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32373325|t=ä. Combination of CT and RT-PCR in the screening or diagnosis of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32147407|t=ä. Diagnosis of SARS-CoV-2 Infection based on CT scan vs RT-PCR: Reflecting on Experience from MERS-CoV |pdf=|usr=}}
| + | |
| − | {{tp|p=32171865|t=2020. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children |pdf=|usr=}}
| + | |
| − | {{tp|p=32142928|t=ä. Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32205140|t=ä. The progression of computed tomographic (CT) images in patients with coronavirus disease (COVID-19) pneumonia: Running title: The CT progression of COVID-19 pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32201155|t=ä. The evolution of CT characteristics in the patients with COVID-19 pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32277968|t=ä. Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32275925|t=ä. Clinical and Imaging features of COVID-19 Patients: Analysis of Data from High-Altitude Areas |pdf=|usr=}}
| + | |
| − | {{tp|p=C7152865|t=ä. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32112884|t=2020. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32109443|t=ä. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2 |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | {{tp|p=32344326|t=2020. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Respiration mgmt]]''' | + | *'''[[Case reports]]''' |
| − | {{tp|p=32339975|t=2020. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32279018|t=ä. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports |pdf=|usr=}}
| + | |
| − | {{tp|p=32317225|t=ä. A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| − | {{tp|p=32300796|t=ä. A geroscience perspective on COVID-19 mortality |pdf=|usr=}}
| |
| − | {{tp|p=32279081|t=ä. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study |pdf=|usr=}}
| |
| − | {{tp|p=32360995|t=ä. No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease |pdf=|usr=}}
| |
| − | {{tp|p=32278005|t=ä. Non-alcoholic fatty liver diseases in patients with COVID-19: A etrospective study |pdf=|usr=}}
| |
| − | {{tp|p=32348791|t=ä. Clinical characteristics of COVID-19 patients with abnormal liver tests |pdf=|usr=}}
| |
| − | {{tp|p=32348790|t=ä. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis |pdf=|usr=}}
| |
| − | {{tp|p=32305291|t=ä. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury |pdf=|usr=}}
| |
| − | {{tp|p=32145216|t=ä. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy |pdf=|usr=}}
| |
| − | {{tp|p=32240670|t=2020. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up |pdf=|usr=}}
| |
| − | {{tp|p=32171866|t=ä. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients |pdf=|usr=}}
| |
| − | {{tp|p=32335173|t=ä. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review |pdf=|usr=}}
| |
| − | {{tp|p=32335169|t=ä. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32305490|t=ä. Risk Factors Associated with Disease Severity and Length of Hospital Stay in COVID-19 Patients |pdf=|usr=}}
| |
| − | {{tp|p=32305487|t=ä. Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China |pdf=|usr=}}
| |
| − | {{tp|p=32294503|t=ä. Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32283158|t=ä. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32179908|t=ä. A 55-Day-Old Female Infant Infected With 2019 Novel Coronavirus Disease: Presenting With Pneumonia, Liver Injury, and Heart Damage |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| − | {{tp|p=32334770|t=2020. The Need to Include Assisted Living in Responding to the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32222763|t=ä. COVID-19 Through the Lens of Gerontology |pdf=|usr=}}
| |
| − | {{tp|p=32305489|t=ä. Clinical characteristics of older patients: The experience of a geriatric short-stay unit dedicated to patients with COVID-19 in France |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32269194|t=2020. Pneumonia Without Respiratory Symptoms |pdf=|usr=}}
| |
| − | {{tp|p=32361703|t=2020. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report |pdf=|usr=}}
| |
| − | {{tp|p=32113824|t=ä. First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan |pdf=|usr=}}
| |
| − | {{tp|p=32334915|t=ä. Letter to the Editor: Update on the followed-up CT exam of the first CoVID-19 pneumonia in Taiwan |pdf=|usr=}}
| |
| − | {{tp|p=32362920|t=2020. Armarium facilitating angina management post myocardial infarction concomitant with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32205138|t=ä. The index case of SARS-CoV-2 in Scotland |pdf=|usr=}}
| |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32302722|t=ä. Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32114054|t=2020. COVID-19 in medical personnel: observation from Thailand |pdf=|usr=}}
| |
| − | {{tp|p=32171869|t=2020. Clinical progression of patients with COVID-19 in Shanghai, China |pdf=|usr=}}
| |
| − | {{tp|p=32272120|t=ä. Critical patients with coronavirus disease 2019: Risk factors and outcome nomogram |pdf=|usr=}}
| |
| − | {{tp|p=32360500|t=ä. Clinical and Transmission Dynamics Characteristics of 406 Children with Coronavirus Disease 2019 in China: A Review |pdf=|usr=}}
| |
| − | {{tp|p=32360498|t=2020. Clinical features of critically ill patients with confirmed COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32353384|t=ä. Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort |pdf=|usr=}}
| |
| − | {{tp|p=32335174|t=ä. Clinical Features and Outcomes of Asymptomatic Cases of SARS-CoV-2 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32335171|t=ä. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China |pdf=|usr=}}
| |
| − | {{tp|p=32335170|t=ä. Characteristics of a family cluster of Severe Acute Respiratory Syndrome Coronavirus 2 in Henan, China |pdf=|usr=}}
| |
| − | {{tp|p=32315724|t=ä. Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32179910|t=ä. Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | {{tp|p=32305438|t=ä. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32290293|t=2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32171450|t=2020. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus |pdf=|usr=}}
| |
| − | {{tp|p=32173287|t=ä. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines |pdf=|usr=}}
| |
| − | {{tp|p=32373322|t=ä. Fighting COVID-19 with water |pdf=|usr=}}''dehydration of mucous glycans''
| |
| − | {{tp|p=32372051|t=ä. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2 |pdf=|usr=}}
| |
| − | {{tp|p=32335161|t=ä. In the search of potential epitopes for Wuhan seafood market pneumonia virus using high order nullomers |pdf=|usr=}}
| |
| − | {{tp|p=32300051|t=2020. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32171872|t=ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study |pdf=|usr=}}
| |
| − | {{tp|p=32333918|t=ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact |pdf=|usr=}}
| |
| − | {{tp|p=32283153|t=ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1 |pdf=|usr=}}
| |
| − | {{tp|p=32362440|t=ä. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases |pdf=|usr=}}
| |
| − | {{tp|p=32232474|t=ä. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure |pdf=|usr=}}
| |
| − | {{tp|p=32348485|t=ä. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients |pdf=|usr=}}
| |
| − | {{tp|p=32348489|t=ä. COVID-19: Is Everything Appropriate to Create an Effective Vaccine?|pdf=|usr=}}
| |
| | | | |
| − | ----
| |
| | | | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| | + | *'''[[Biophysics of aerosols]]''' |
| | | | |
| | | | |
| − |
| |
| − |
| |
| − | *'''[[Remission, recurrence and persistence]]'''
| |
| − | {{tp|p=32200109|t=2020. SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge |pdf=|usr=}}
| |
| − | {{tp|p=32251796|t=ä. The enlightenment from two cases of asymptomatic infection with SARS-CoV-2: is it safe after 14 days of isolation?|pdf=|usr=}}
| |
| − | {{tp|p=32147538|t=2020. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report |pdf=|usr=}}
| |
| − | {{tp|p=32340768|t=ä. Risk of reactivation or reinfection of novel coronavirus (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32314129|t=ä. A Case Series of Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients |pdf=|usr=}}
| |
| − | {{tp|p=32171867|t=2020. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation |pdf=|usr=}}
| |
| − | {{tp|p=32209381|t=ä. Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients |pdf=|usr=}}
| |
| − | {{tp|p=32335176|t=ä. Positive rectal swabs in young patients recovered from coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32289343|t=ä. Recurrent PCR positivity after hospital discharge of people with coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32283161|t=ä. Duration for carrying SARS-CoV-2 in COVID-19 patients |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[Other routes of infection]]'''
| |
| − | {{tp|p=32335340|t=ä. Potential Fecal Transmission of SARS-CoV-2: Current Evidence and Implications for Public Health |pdf=|usr=}}
| |
| − | {{tp|p=32278800|t=ä. Sexual transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A new possible route of infection?|pdf=|usr=}}
| |
| − | {{tp|p=32329026|t=ä. Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab |pdf=|usr=}}
| |
| − | {{tp|p=32315667|t=ä. Put a lid on it: Are faecal bio-aerosols a route of transmission for SARS-CoV-2?|pdf=|usr=}}
| |
| − | {{tp|p=32145217|t=2020. Public health might be endangered by possible prolonged discharge of SARS-CoV-2 in stool |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | *'''[[Biophysics of aerosols]]'''
| |
| − | {{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}}
| |
| − | {{tp|p=32360356|t=ä. Putting some context to the aerosolization debate around SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32142885|t=2020. Association between 2019-nCoV transmission and N95 respirator use |pdf=|usr=}}
| |
| − | {{tp|p=32201338|t=ä. Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy |pdf=|usr=}}
| |
| − | {{tp|p=32035997|t=2020. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents |pdf=|usr=}}
| |
| − | {{tp|p=32277965|t=ä. Disinfection of N95 respirators by ionized hydrogen peroxide during pandemic coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32277964|t=ä. Sterilization of disposable face masks by means of standardized dry and steam sterilization processes; an alternative in the fight against mask shortages due to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32348833|t=ä. What face mask for what use in the context of COVID-19 pandemic? The French guidelines |pdf=|usr=}}
| |
| − | {{tp|p=32360355|t=ä. COVID-19-associated shortage of alcohol-based hand rubs, face masks, medical gloves and gowns ? proposal for a risk-adapted approach to ensure patient and healthcare worker safety |pdf=|usr=}}
| |
| − | {{tp|p=32304726|t=ä. Innovative technologies for hand hygiene monitoring are urgently needed in the fight against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32301491|t=ä. Airborne or droplet precautions for health workers treating COVID-19?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32347453|t=ä. Redesigning a Department of Surgery during the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32314235|t=ä. Practical Implications of Novel Coronavirus COVID-19 on Hospital Operations, Board Certification, and Medical Education in Surgery in the USA |pdf=|usr=}}
| |
| − | {{tp|p=32285338|t=ä. What Is the Appropriate Use of Laparoscopy over Open Procedures in the Current COVID-19 Climate?|pdf=|usr=}}
| |
| − | {{tp|p=32340908|t=ä. Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States |pdf=|usr=}}
| |
| − | {{tp|p=32273247|t=ä. Challenges with the management of older patients with cancer during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32331928|t=ä. Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma |pdf=|usr=}}
| |
| − | {{tp|p=32327321|t=ä. Development of a telehealth geriatric assessment model in response to the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32246144|t=ä. The Impact of the COVID-19 Pandemic on Disabled and Hospice Home Care Patients |pdf=|usr=}}
| |
| − | {{tp|p=32314784|t=ä. A Frail Health Care System for an Old Population: Lesson form the COVID-19 Outbreak in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32353526|t=ä. Continues Renal Replacement Therapy (CRRT) With Disposable Hemoperfusion Cartridge: A Promising Option for Severe COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32373323|t=ä. Saving the frontline health workforce amidst the COVID-19 crisis: Challenges and recommendations |pdf=|usr=}}
| |
| − | {{tp|p=32298769|t=ä. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care |pdf=|usr=}}
| |
| − | {{tp|p=32169615|t=ä. Makeshift hospitals for COVID-19 patients: where health-care workers and patients need sufficient ventilation for more protection |pdf=|usr=}}
| |
| − | {{tp|p=32283134|t=ä. Highlights for management of patients with Autoimmune Liver Disease during COVID-19 pandemia |pdf=|usr=}}
| |
| − | {{tp|p=32142887|t=ä. Practical experiences and suggestions for the ?eagle-eyed observer?: a novel promising role for controlling nosocomial infection in the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32142886|t=ä. Effective strategies to prevent coronavirus disease-2019 (COVID-19) outbreak in hospital |pdf=|usr=}}
| |
| − | {{tp|p=32243949|t=ä. Ark of Life and Hope: the role of the Cabin Hospital in facing COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32205162|t=ä. Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre |pdf=|usr=}}
| |
| − | {{tp|p=32205161|t=ä. Strategies for qualified triage stations and fever clinics during the outbreak of COVID-2019 in the county hospitals of Western Chongqing |pdf=|usr=}}
| |
| − | {{tp|p=32278704|t=ä. Body Temperature Measurement to Prevent Pandemic COVID-19 in Hospitals in Taiwan: Repeated Measurement is Necessary |pdf=|usr=}}
| |
| − | {{tp|p=32151674|t=ä. Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a question needing an answer |pdf=|usr=}}
| |
| − | {{tp|p=32259547|t=ä. COVID-19 contagion and contamination through hands of trauma patients: what risks and what precautions?|pdf=|usr=}}
| |
| − | {{tp|p=32360337|t=ä. Factors Associated with Preventive Behaviours of COVID-19 among Hospital Staff in Iran in 2020: An Application of the Protection Motivation Theory |pdf=|usr=}}
| |
| − | {{tp|p=32339619|t=ä. Infection prevention partners up with psychology in a Danish Hospital successfully addressing staffs fear during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32339615|t=2020. COVID-19: how prepared are front-line healthcare workers in England?|pdf=|usr=}}
| |
| − | {{tp|p=32304725|t=ä. Environmental virus surveillance in the isolation ward of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32302723|t=ä. Preparedness for COVID-19 infection prevention in Korea: Single-center experience |pdf=|usr=}}
| |
| − | {{tp|p=C7152925|t=ä. Minimising intra-hospital transmission of COVID-19: the role of social distancing |pdf=|usr=}}
| |
| − | {{tp|p=32223581|t=ä. International Perspectives Concerning Donor Milk Banking During the SARS-CoV-2 (COVID-19) Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32360881|t=ä. Environmental Contamination of SARS-CoV-2 in Healthcare Premises |pdf=|usr=}}
| |
| − | {{tp|p=32251688|t=ä. China empowers Internet hospital to fight against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32335177|t=ä. The economics of infection prevention: why it is crucial to invest in hand hygiene and nurses during the novel coronavirus pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32298677|t=ä. Clinical characteristics and prognosis in cancer patients with COVID-19: A single center s retrospective study |pdf=|usr=}}
| |
| | | | |
| − | {{tp|p=32283160|t=ä. Airborne precautions recommended in Wuhan, China for bedside fiberoptic bronchoscopy examination of patients with COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Mental aspects of health professionals]]''' |
| | | | |
| | + | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| − | *'''[[Mental aspects of health professionals]]'''
| |
| − | {{tp|p=32259628|t=ä. Clinician Wellness During the COVID-19 Pandemic: Extraordinary Times and Unusual Challenges for the Allergist/Immunologist |pdf=|usr=}}
| |
| − | {{tp|p=32208139|t=ä. Coronavirus Disease 2019 (COVID-19) and Beyond: Micropractices for Burnout Prevention and Emotional Wellness |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | | | |
| | | | |
| − | *'''[[Socio-psychiatric aspects of the status hygienicus]]'''
| |
| − | {{tp|p=32307522|t=ä. Assessing the Impact of the COVID-19 Pandemic and Accompanying Mitigation Efforts on Older Adults |pdf=|usr=}}
| |
| − | {{tp|p=32296840|t=ä. Aging in Times of the COVID-19 Pandemic: Avoiding Ageism and Fostering Intergenerational Solidarity |pdf=|usr=}}
| |
| − | {{tp|p=32282920|t=ä. ?We?re staying at home? Association of self-perceptions of aging, personal and family resources and loneliness with psychological distress during the lock-down period of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32355556|t=ä. Impact of coronavirus outbreak on psychological health |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Avoiding clinical medicine in other diseases]]''' | + | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| − | {{tp|p=32283124|t=ä. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| − |
| |
| − | *'''[[Occupational medicine, workplace security and status hygienicus]]'''
| |
| − | {{tp|p=32147406|t=ä. Reasons for healthcare workers becoming infected with novel coronavirus disease 2019 (COVID-19) in China |pdf=|usr=}}
| |
| − | {{tp|p=32243947|t=ä. Beyond the assistance: additional exposure situations to COVID-19 for healthcare workers |pdf=|usr=}}
| |
| − | {{tp|p=32278703|t=ä. Preventing the Transmission of COVID-19 Amongst Healthcare Workers |pdf=|usr=}}
| |
| − | {{tp|p=32278701|t=ä. Knowledge, attitude and practice regarding COVID-19 among health care workers in Henan, China |pdf=|usr=}}
| |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32325710|t=2020. The COVID-19 Outbreak and Affected Countries Stock Markets Response |pdf=|usr=}}
| |
| − | {{tp|p=32305533|t=ä. The Socio-Economic Implications of the Coronavirus and COVID-19 Pandemic: A Review |pdf=|usr=}}
| |
| − | {{tp|p=32292707|t=ä. Death and contagious infectious diseases: Impact of the COVID-19 virus on stock market returns |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| Zeile 340: |
Zeile 147: |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32277970|t=ä. Strategies to trace back the origin of COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32373340|t=ä. Epidemiological analysis of the early 38 fatalities in Hubei, China, of the coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32373339|t=ä. More effective strategies are required to strengthen public awareness of COVID-19: Evidence from Google Trends |pdf=|usr=}}
| |
| − | {{tp|p=32373318|t=ä. The COVID-19 containment in Vietnam: What are we doing?|pdf=|usr=}}
| |
| − | {{tp|p=32257174|t=ä. When will the battle against novel coronavirus end in Wuhan: A SEIR modeling analysis |pdf=|usr=}}
| |
| − | {{tp|p=32277963|t=ä. Super-spreading events and contribution to transmission of MERS, SARS, and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32259546|t=ä. Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong |pdf=|usr=}}
| |
| − | {{tp|p=32092368|t=2020. The non-contact handheld cutaneous infra-red thermometer for fever screening during the COVID-19 global emergency |pdf=|usr=}}
| |
| − | {{tp|p=32057788|t=2020. Novel coronavirus, poor quarantine, and the risk of pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32119884|t=2020. Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission |pdf=|usr=}}
| |
| − | {{tp|p=32112887|t=2020. Simulating and forecasting the cumulative confirmed cases of SARS-CoV-2 in China by Boltzmann function-based regression analyses |pdf=|usr=}}
| |
| − | {{tp|p=32209384|t=ä. Wuhan and Hubei COVID-19 mortality analysis reveals the critical role of timely supply of medical resources |pdf=|usr=}}
| |
| − | {{tp|p=32209383|t=ä. Herd immunity ? estimating the level required to halt the COVID-19 epidemics in affected countries |pdf=|usr=}}
| |
| − | {{tp|p=32092391|t=ä. Novel coronavirus (2019-nCoV) cases in Hong Kong and implications for further spread |pdf=|usr=}}
| |
| − | {{tp|p=32277969|t=ä. The Role of Phylogenetic Analysis in Clarifying the Infection Source of a COVID-19 Patient |pdf=|usr=}}
| |
| − | {{tp|p=32268181|t=ä. The role of close contacts tracking management in COVID-19 prevention: A cluster investigation in Jiaxing, China |pdf=|usr=}}
| |
| − | {{tp|p=32360879|t=ä. Unintended Consequence: Influenza plunges with public health response to COVID-19 in Singapore |pdf=|usr=}}
| |
| − | {{tp|p=32360497|t=ä. The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France |pdf=|usr=}}
| |
| − | {{tp|p=32335172|t=ä. Personal respirators for population level control of the COVID19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32335167|t=ä. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32325130|t=ä. Bayesian phylodynamic inference on the temporal evolution and global transmission of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32305488|t=ä. Flattening-the-curve associated with reduced COVID-19 case fatality rates- an ecological analysis of 65 countries |pdf=|usr=}}
| |
| − | {{tp|p=32302605|t=ä. Global COVID-19 fatality analysis reveals Hubei-like countries potentially with severe outbreaks |pdf=|usr=}}
| |
| − | {{tp|p=32283165|t=ä. A cluster of the Corona Virus Disease 2019 caused by incubation period transmission in Wuxi, China |pdf=|usr=}}
| |
| − | {{tp|p=32235084|t=2020. Spatial-temporal distribution of COVID-19 in China and its prediction: A data-driven modeling analysis |pdf=|usr=}}
| |
| − | {{tp|p=32088679|t=2020. 2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness |pdf=|usr=}}
| |
| − | {{tp|p=32146445|t=2020. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China |pdf=|usr=}}
| |
| − | {{tp|p=32379708|t=2020. Sustainable health promotion for the seniors during COVID-19 outbreak: a lesson from Tokyo |pdf=|usr=}}
| |
| − | {{tp|p=32379707|t=2020. Examining the incubation period distributions of COVID-19 on Chinese patients with different travel histories |pdf=|usr=}}
| |
| − | {{tp|p=32193550|t=ä. Public Health Measures to Slow Community Spread of Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32067043|t=ä. A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period |pdf=|usr=}}
| |
| − | {{tp|p=32339231|t=ä. Epidemiological characteristics and incubation period of 7,015 confirmed cases with Coronavirus Disease 2019 outside Hubei Province in China |pdf=|usr=}}
| |
| − | {{tp|p=32319519|t=ä. Transmission potential of asymptomatic and paucisymptomatic SARS-CoV-2 infections: a three-family cluster study in China |pdf=|usr=}}
| |
| − | {{tp|p=32318703|t=ä. Epidemiological and clinical characteristics of 26 asymptomatic SARS-CoV-2 carriers |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 383: |
Zeile 154: |
| | | | |
| | | | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | | | |
| − | *'''[[Failure of politics and public health guidance]]'''
| |
| − | {{tp|p=32373315|t=ä. The need to improve the laws and regulations relevant to the outbreak of COVID-19: What might be learned from China?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32316647|t=2020. Using Social Media to Mine and Analyze Public Opinion Related to COVID-19 in China |pdf=|usr=}}
| + | |
| − | *[https://www.businessinsider.com/nearly-half-of-reopen-america-twitter-accounts-are-bots-report-2020-5?utmSource=twitter&utmContent=referral&utmTerm=topbar&referrer=twitter twitter botwar]
| + | |
| − | *[https://www.frontpagemag.com/point/2020/05/obama-clinton-9th-circuit-judges-suspend-bill-daniel-greenfield/ judges declare the Bill of Rights is suspended until the Coronavirus is cured]
| + | |
| − | *[http://freerepublic.com/focus/f-news/3848303/posts They want you divided, and focused on other enemies.]
| + | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| − | {{tp|p=32142979|t=2020. Li Wenliang, a face to the frontline healthcare worker The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32271208|t=ä. Survey of COVID-19 Disease Among Orthopaedic Surgeons in Wuhan, People?s Republic of China |pdf=|usr=}}
| |
| − | {{tp|p=32277966|t=ä. Characteristics of deaths amongst health workers in China during the outbreak of COVID-19 infection |pdf=|usr=}}
| |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32120913|t=2020. Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019?2020 |pdf=|usr=}}
| |
| − | {{tp|p=32001309|t=2020. Emergence of a novel coronavirus causing respiratory illness from Wuhan, China |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32315025|t=ä. After the COVID-19 Pandemic: The Next Wave of Health Challenges for Older Adults |pdf=|usr=}}
| + | |
| − | {{tp|p=32156648|t=ä. 2019-novel coronavirus outbreak: A new challenge |pdf=|usr=}}
| + | |
| − | {{tp|p=32355555|t=ä. COVID-19 must catalyse key global natural experiments |pdf=|usr=}}
| + | |
| − | {{tp|p=32145214|t=2020. Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32092388|t=2020. Chinese medical personnel against the 2019-nCoV |pdf=|usr=}}
| + | |
| − | {{tp|p=32235086|t=2020. As COVID-19 cases, deaths and fatality rates surge in Italy, underlying causes require investigation |pdf=|usr=}}
| + | |
| − | {{tp|p=32235085|t=2020. The novel zoonotic COVID-19 pandemic: An expected global health concern |pdf=|usr=}}
| + | |
| − | {{tp|p=32235083|t=2020. Global outbreak of COVID-19: a new challenge?|pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[lifechemicals.com antiviral candidate drugs]
| |
| − | *[biomol.com assays cytokines general spectrum]
| |
| − | *[labospace.com custom single probe assay 400 possible cytokines and so on]
| |
| − | *[codexdna.com dna synthesis]
| |
| − | *
| |
| | | | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
